



**Contact:**

Dr. Misha Plam

President & CEO

T: (303) 641-3669

[misha.plam@amidebio.com](mailto:misha.plam@amidebio.com)

[www.amidebio.com](http://www.amidebio.com)

**AmideBio Obtains Composition of Matter Patent for Novel Single Chain Insulins**

**BOULDER, CO, May 4, 2015** – AmideBio, LLC, a privately held biopharmaceutical company, announced today that the U.S. Patent and Trademark Office (USPTO) has issued United States Patent 9,006,176 titled “Chemically and thermodynamically stable insulin analogues and improved methods for their production”. The patent expands the use of the companies patented core platform technology to high value biopharmaceutical markets such as diabetes. The composition of matter patent covers a large library of thermostable single chain Insulins showing improved stability that enables improved formulation capabilities for high concentration insulin solutions and pump applications.

“Issuance of this U.S. patent represents a key milestone for AmideBio in our efforts to implement our core platform technology to bring improved insulins to the marketplace” said Dr. Misha Plam, AmideBio’s President and CEO. “Our recent research focus has been on novel Thermostable Single Chain Insulins for the treatment of diabetes and our preclinical data has demonstrated the dramatically improved stability of our novel insulins as well as the biological efficacy for both long-acting and short-acting activities. We are currently pursuing potential partnership and license arrangements with pharmaceutical and biotechnology companies in the diabetes space.”

The novel single chain insulins were developed at AmideBio and enabled by the previously granted United States Patent 8,796,431 developed under the scientific leadership of Dr. Michael Stowell, Associate Professor of MCD Biology and Mechanical Engineering at the University of Colorado, and the Company’s CTO and founder. United States Patent 8,796,431 has been licensed from the University of Colorado.

**About AmideBio:**

AmideBio, based in Boulder, CO, is a biotechnology company leveraging its proprietary BioPure™ platform technology to deliver difficult-to-manufacture peptides and build a pipeline of novel biotherapeutics. AmideBio's proprietary technology enables the rapid and economical manufacture of pure peptides of any length. This innovative technology combines recombinant and chemical methods, eliminates many of the inefficient and costly steps of processes that rely only on one or the other approach, results in fewer batch inconsistencies and less waste generation. Such advantages enable AmideBio to offer its cost-efficient technology and peptide product candidates to the pharmaceutical and biotech industry. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at metabolic, inflammatory and neurodegenerative diseases.

- ENDS -